| Affiliation: | aLaboratory of Glycochemistry and Asymmetric Synthesis, Swiss Federal Institute of Technology (EPFL), Batochime, CH-1015 Lausanne, Switzerland;bNational Cancer Research Institute, 16132 Genoa, Italy;cDepartment of Internal Medicine, University of Genoa, Italy;dService and Central Laboratory of Hematology, University Hospital (CHUV), Lausanne, Switzerland;eDepartment of Experimental Medicine, University of Genoa, Italy;fNovartis, Institutes for Biomedical Research, CH-4002 Basel, Switzerland |
| Abstract: | New derivatives of 1,4-dideoxy-1,4-imino-d-ribitol have been prepared and evaluated for their cytotoxicity on solid and haematological malignancies. 1,4-Dideoxy-5-O-[(9Z)-octadec-9-en-1-yl]-1,4-imino-d-ribitol (13, IC50 ∼2 μM) and its C18-analogues (IC50 <10 μM) are cytotoxic toward SKBR3 (breast cancer) cells. 13 also inhibits (IC50 ∼8 μM) growth of JURKAT cells. |
